In this article (Mol Cancer Ther 2005;4:1399–408), which was published in the September 2005 issue of Molecular Cancer Therapeutics (1), the authors discovered errors in three figure panels.

The image originally published as Fig. 2A was from the wrong xenograft tumor tissue. The authors completed two cell lines–derived xenografts at the same time and mismatched the data. As a result, Fig. 2A is incorrect. In the corrected Fig. 2A, experiments were performed with A549 and H1299 cell lines under identical conditions as indicated before. Invasion assays were performed for H1299 lung cancer cells. The new data were generated to confirm and verify the effect of Ad-uPAR and Ad-uPAR-MMP-9 on invasion. The data obtained reconfirm the results originally reported in the article (the authors state they observed more than 85% suppression) on cell invasion in both the cases. Figure 2B is corrected in order that the data in the graph correspond with the corrected Fig. 2A.

Figure 2.

Ad-uPAR-MMP-9 inhibits lung cancer cell invasiveness through Matrigel. H1299 cells were trypsinized and counted 3 days after infection with mock, Ad-EV, or the indicated doses of Ad-uPAR and Ad-uPAR-MMP-9. Invasion assays were carried out in 12-well Transwell units (1 × 106 cells per treatment condition in triplicate). After a 24-hour incubation period, the cells that had passed through the filter into the bottom wells were fixed and photographed (A). The percentage of invasion was quantitated as described in Materials and Methods (B). Columns, mean of five different experiments; bars, SD.

Figure 2.

Ad-uPAR-MMP-9 inhibits lung cancer cell invasiveness through Matrigel. H1299 cells were trypsinized and counted 3 days after infection with mock, Ad-EV, or the indicated doses of Ad-uPAR and Ad-uPAR-MMP-9. Invasion assays were carried out in 12-well Transwell units (1 × 106 cells per treatment condition in triplicate). After a 24-hour incubation period, the cells that had passed through the filter into the bottom wells were fixed and photographed (A). The percentage of invasion was quantitated as described in Materials and Methods (B). Columns, mean of five different experiments; bars, SD.

Close modal

In Fig. 5, the experiments were performed with in A549 and H1299 and obtained identical results. Figure 5C image was represented incorrectly.

Figure 5.

Inhibition of subcutaneous tumor growth. A, nude mice were injected with H1299 cells (5 × 106/100 μL). When the tumor reached 5 to 6 mm in size, mice were injected intratumorally with Ad-EV (5 × 109) or Ad-uPAR-MMP-9 (5 × 108 or 5 × 109) thrice. Tumor size was measured using calipers as described in Materials and Methods. B and C, inhibition of subcutaneous tumor growth and lung metastasis. A549 cells were injected subcutaneous into nude mice. After 2 weeks, the mice received intravenous injections of PBS or 5 × 108 PFU of either Ad-EV or Ad-uPAR-MMP-9 thrice at 5-day intervals. Representative subcutaneous tumors are shown for each treatment condition (B). H&E staining of lung sections from the same mice (C).

Figure 5.

Inhibition of subcutaneous tumor growth. A, nude mice were injected with H1299 cells (5 × 106/100 μL). When the tumor reached 5 to 6 mm in size, mice were injected intratumorally with Ad-EV (5 × 109) or Ad-uPAR-MMP-9 (5 × 108 or 5 × 109) thrice. Tumor size was measured using calipers as described in Materials and Methods. B and C, inhibition of subcutaneous tumor growth and lung metastasis. A549 cells were injected subcutaneous into nude mice. After 2 weeks, the mice received intravenous injections of PBS or 5 × 108 PFU of either Ad-EV or Ad-uPAR-MMP-9 thrice at 5-day intervals. Representative subcutaneous tumors are shown for each treatment condition (B). H&E staining of lung sections from the same mice (C).

Close modal

The authors apologize for the errors, and present correct figures below.

1.
Rao
JS
,
Gondi
C
,
Chetty
C
,
Chittivelu
S
,
Joseph
PA
,
Lakka
SS
. 
Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non–small cell lung cancer cells
.
Mol Cancer Ther
2005
;
4
:
1399
408
.